0000000000764648

AUTHOR

Gabriele Doering

showing 1 related works from this author

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TR…

2016

5522Background: Sorafenib (S), a multi TK-inhibitor in combination with topotecan (T), a topoisomerase inhibitor showed preclinical synergistic effects in ovarian cancer but critical toxicity. To a...

SorafenibOncologyCancer Researchmedicine.medical_specialty030219 obstetrics & reproductive medicineendocrine system diseasesmedicine.drug_classbusiness.industryPlacebomedicine.diseasefemale genital diseases and pregnancy complicationsDouble blind03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineToxicitymedicineTopotecanbusinessOvarian cancerTopoisomerase inhibitormedicine.drugPlatinum resistantJournal of Clinical Oncology
researchProduct